Interstitial lung diseases (ILDs) encompass more than 200 disorders that can lead to inflammation and irreversible scarring of lung tissue, negatively impacting lung function. A subgroup of these can get worse over time leading to progressive fibrosing ILD (PF-ILD. Most are challenging to identify and accurately diagnose – but a unique public-private philanthropic partnership is bringing new hope to patients and their families.
The Alberta Boehringer Ingelheim Interstitial Lung Disease (ABILD) partnership is a collaboration with Boehringer Ingelheim Canada, the University Hospital Foundation and the Respiratory Division of Medicine Strategic Clinical Network (Alberta Health Services). The initiative is focused on advancing health innovation projects to gain a better understanding of care gaps in diagnosis, care and access to treatment for Albertans living with progressive fibrosing interstitial lung disease (ILD). It aims to optimize care across the healthcare system by defining the epidemiology of ILD and enhancing the clinical care pathway for patients.
Credit: University Hospital Foundation
This collaboration is an example of how strategic public-private partnerships aimed at delivering patient-centric models of care can expand efforts to find innovative solutions for today’s health care challenges to help improve the healthcare system. Learn more about the partnership.